Skip to main content
. 2023 Aug 10;14:1213792. doi: 10.3389/fpsyg.2023.1213792

Table 1.

Characteristics of the trial sample (ITT, n = 36).

Variables HT (n = 18) WL (n = 18) Epigenetic sample (n = 17) Total (n = 36)
M (SD) M (SD) M (SD) M (SD)
Age 40.28 (13.33) 43.78 (16.97) 36.65 (14.17) 42.03 (15.14)
No. (%) No. (%) No. (%) No. (%)
Sex, female 17 (94.44) 12 (66.67) 14 (82.35) 29 (80.56)
Antidepressant medication (AD) 3 (16.67) 3 (16.67) 3 (17.65) 6 (16.67)
SSRI 2 (11.11) 3 (16.67) 3 (17.65) 5 (13.89)
Tricyclic AD 1 (5.56) 0 (0.00) 0 (0.00) 1 (2.78)
Comorbidity 16 (88.89) 14 (77.78) 8 (47.06) 30 (83.33)
Currenta 11 (61.11) 8 (44.44) 5 (29.41) 19 (52.78)
Panic disorder 9 (50.00) 3 (16.67) 3 (17.65) 12 (33.33)
Panic attacks 2 (11.11) 3 (16.67) 0 (0.00) 5 (13.89)
Social phobia 0 (0.00) 1 (5.56) 0 (0.00) 1 (2.78)
Obsessive PS 0 (0.00) 1 (5.56) 0 (0.00) 1 (2.78)
Only lifetime/previousa 7 (38.89) 11 (61.11) 11 (64.71) 18 (50.00)
Panic disorder 3 (16.67) 6 (33.33) 5 (29.41) 9 (25.00)
Panic attacks 0 (0.00) 1 (5.56) 1 (5.88) 1 (2.78)
Major depression 4 (22.22) 4 (22.22) 5 (29.41) 8 (22.22)

M, mean; SD, standard deviation; No., number; HT, hypnotherapy; WL, waitlist control group; SSRI, selective serotonin reuptake inhibitor; PS, personality disorder.

a

Double entry possible meaning a patient could have a current but also a lifetime/previous comorbid disorder.